Status:
ENROLLING_BY_INVITATION
An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition
Lead Sponsor:
Chi-Chang Huang
Collaborating Sponsors:
Bened Biomedical Co., Ltd.
Conditions:
Subjective Cognitive Decline (SCD)
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to eval...
Detailed Description
Lacticaseibacillus paracasei PS23 (PS23) is a specific strain of probiotic bacteria known for its potential health benefits, particularly in the context of aging and muscle health. Research suggests t...
Eligibility Criteria
Inclusion
- Adults aged 50 to 85 years who self-report experiencing signs of cognitive decline.
- No prior diagnosis of dementia or Alzheimer's disease (AD).
- Willing and able to comply with study assessments and requirements, and provide written informed consent.
Exclusion
- Use of antibiotics or probiotic powder, capsules, or tablets within the past month.
- Currently undergoing antibiotic treatment.
- Known allergy to dairy products.
- Presence of immunodeficiency or impaired immune function.
- Diagnosis of small intestinal bacterial overgrowth (SIBO).
- Determined unsuitable by the investigator, for example, initiation of any new medication or therapy during the study period, particularly those related to memory impairment or cognitive decline.
Key Trial Info
Start Date :
October 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07168824
Start Date
October 17 2025
End Date
December 31 2026
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Graduate Institute of Sports Science, National Taiwan Sport University
Taoyuan District, Taiwan, 33301